June 27, 2026
The conversation goes like this: you mention weight gain to your doctor. Your doctor notes you have PCOS. You are told to lose weight, exercise more, and eat less. You already know this. You are already trying. The weight does not move — or it moves briefly and then comes back. And you are left wondering whether you are doing something wrong. You are not. Standard weight loss advice fails PCOS patients systemically because it treats a metabolic-hormonal condition as a simple energy balance problem.
Up to 70% of women with PCOS have insulin resistance — elevated fasting insulin and impaired cellular glucose uptake — that fundamentally changes how the body responds to caloric deficit. In a normal metabolic state, caloric restriction prompts the body to access stored fat for energy. In an insulin-resistant state, chronically elevated insulin keeps the body in storage mode — fat cells respond more readily to insulin's fat-storage signals than to the release signals of an energy deficit. The result: a woman with PCOS and significant insulin resistance can eat at the same caloric deficit as a metabolically normal woman and achieve significantly less fat loss, because the hormonal environment is not conducive to fat release. This is not a character failing. It is measurable physiology. Read our PCOS pillar for the complete context: PCOS support and hormone balance in India.
Excess testosterone and other androgens — elevated in most PCOS patients — specifically promote fat storage in the abdominal region and impair fat metabolism. This explains the characteristic body composition of many PCOS patients: significant abdominal fat accumulation even without total body obesity. Androgens also promote muscle breakdown in the context of insulin resistance, reducing the muscle mass that is the primary determinant of long-term metabolic rate. Standard calorie-counting approaches do not address the androgen driver of this fat distribution pattern.
Carbohydrate quality, not just quantity. The most evidence-backed dietary approach for PCOS weight management focuses on reducing the glycaemic load of meals — lowering refined carbohydrate intake while maintaining adequate total carbohydrates through whole food sources (legumes, whole grains, vegetables). This specifically targets insulin response rather than total caloric intake. A low-glycaemic approach consistently outperforms a standard low-calorie approach for insulin-resistant PCOS patients in clinical trials.
Resistance training over cardio. Cardio burns calories during the session; resistance training builds muscle that burns more calories continuously — and crucially, drives glucose into muscle cells through insulin-independent pathways, directly improving insulin sensitivity over time. For PCOS patients, resistance training is the most metabolically targeted exercise choice.
Inositol. Myo-inositol and d-chiro-inositol — either separately or in combination — have the most robust clinical evidence of any supplement in PCOS management, with multiple randomised controlled trials demonstrating improvements in insulin sensitivity, menstrual regularity, and androgen levels. ALIV's PCOS Balancer IV addresses the specific nutrient deficiencies — including magnesium, B vitamins, and vitamin D — that compound insulin resistance in PCOS alongside this foundational approach.
Sleep. PCOS is associated with higher rates of sleep-disordered breathing (sleep apnoea) than the general population — and sleep apnoea dramatically worsens insulin resistance. Screening for sleep apnoea in PCOS patients who are significantly overweight and report non-restorative sleep is basic good clinical practice.
Meaningfully slower than for metabolically normal women — often one-third to one-half the rate for the same level of caloric deficit. Managing this expectation is essential: a PCOS patient losing 0.3–0.5kg per week consistently is making good metabolic progress. The standard expectation of 0.5–1kg per week applies to metabolically normal individuals and is an unrealistic benchmark for women with significant insulin resistance.
The oral contraceptive pill manages PCOS symptoms — regulating cycles, reducing androgen effects on skin and hair — but does not address insulin resistance, the primary metabolic driver. Some oral contraceptives (particularly those with androgenic progestogens) can worsen insulin resistance. The pill is a symptom management tool, not a metabolic treatment for PCOS.
Metformin — an insulin-sensitising medication — is often prescribed for PCOS patients with significant insulin resistance. It improves insulin sensitivity, can modestly support weight loss, and may improve menstrual regularity. The decision to use metformin in PCOS is a clinical one made by the treating specialist based on the specific clinical picture. It is not a substitute for dietary and lifestyle change — it works best alongside these interventions.
Yes — and this is one of the most clinically encouraging facts about PCOS. A weight loss of 5–10% of body weight in overweight PCOS patients is associated with significant improvements in menstrual regularity, androgen levels, and insulin sensitivity in multiple clinical studies. The first 5% of weight loss produces disproportionate metabolic benefit. Even before significant scale change, metabolic improvements from dietary and exercise change produce meaningful symptom improvement in many patients.
Intermittent fasting (time-restricted eating) shows some evidence for improving insulin sensitivity in PCOS — but extended or aggressive fasting can worsen cortisol elevation and disrupt hormonal patterns in some women. For PCOS patients, consistent meal timing with carbohydrate-quality management is generally more sustainable and less hormonally disruptive than aggressive fasting protocols. Discuss any fasting approach with your ALIV doctor or treating specialist before implementing